Bimetallic FeCu-MOF derivatives as heterogeneous catalysts with enhanced stability for electro-Fenton degradation of lisinopril.

A bimetallic FeCu/NC core-shell catalyst, consisting in nanoparticles where zero-valent Fe and Cu atoms, slightly oxidized on their surface, are encapsulated by carbon has been successfully prepared by modifying the synthesis route of MIL(Fe)-88B. FeCu/NC possessed well-balanced textural and electrochemical properties. According to voltammetric responses, in-situ Fe(III) reduction to Fe(II) by low-valent Cu was feasible, whereas the high double-layer capacitance confirmed the presence of a great number of electroactive sites that was essential for continuous HO activation to OH via Fenton's reaction.

Mineralization of Acid Red 1 azo dye by solar photoelectro-Fenton-like process using electrogenerated HClO and photoregenerated Fe(II).

The degradation of Acid Red 1 (AR1) azo dye by solar photoelectro-Fenton-like (SPEF-like) process involving continuously electrogenerated hypochlorous acid (HClO) and photoregenerated Fe(II) to yield hydroxyl radicals, has been studied. The assays were made in a flow plant that included a filter-press cell equipped with a Ti|Ir-Sn-Sb oxide anode, to oxidize Cl ion to HClO, and a stainless-steel cathode. The cell was coupled to a compound parabolic collector (CPC) photoreactor, in series with a reservoir containing 6 L of solution.

Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria. URTILOR study group.

Mizolastine, a new second-generation H1 receptor antagonist with additional anti-allergic properties, was compared with loratadine in 61 patients suffering from severe chronic idiopathic urticaria (CIU). In this double-blind study, patients were randomly allocated to receive either mizolastine 10 mg (n = 26) or loratadine 10 mg (n = 35) once-daily for 28 days. Both compounds were well tolerated, safe and efficacious.

QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamine.

Background: Some H1 antihistamines are at risk for rare but severe dysrhythmias due to an effect on the ventricular repolarization.

Objective: To present an overview of the QT interval monitoring performed during the clinical development of mizolastine, a new selective second-generation H1 antihistamine.

Methods: The ECGs database analysis of clinical studies conducted in volunteers and patients is summarized and focused on the results of reported studies and studies specifically designed for the assessment of the effect of mizolastine on cardiac repolarization, through the QT interval measurements.

Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjunctivitis. RIPERAN Study Group.

Background: Mizolastine is a new, nonsedating antihistamine with additional anti-inflammatory properties, providing relief in allergic rhinitis and urticaria. The aim of this study was to determine the efficacy and safety of 10 mg o.d.